Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80188
Name chronic myelomonocytic leukemia
Definition A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia chronic leukemia chronic myelomonocytic leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FLT3 exon 14 ins FLT3 A848P Sorafenib + Sunitinib chronic myelomonocytic leukemia predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01773395 Phase II Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus GVAX vs. Placebo for MDS/AML After Allo HSCT Terminated USA 0
NCT01787487 Phase II Azacitidine + Ruxolitinib Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm Recruiting USA 0
NCT02193958 Phase Ib/II FF-10501-01 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Completed USA 0
NCT02268253 Phase II Tagraxofusp-erzs Tagraxofusp (SL-401) in Patients With CMML or MF Completed USA | CAN 0
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Active, not recruiting USA 0
NCT02546284 Phase I LAM-003 Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) Completed USA 0
NCT02717884 Phase Ib/II Cytarabine + Tranylcypromine + Tretinoin Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (TRANSATRA) Unknown status DEU 0
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy in CBT Recruiting USA 0
NCT02749708 Phase Ib/II IRX5183 Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Terminated USA 0
NCT02841540 Phase I H3B-8800 A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Terminated USA | ITA | FRA | ESP | BEL 2
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed USA 0
NCT03047993 Phase Ib/II Azacitidine + Telaglenastat Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Completed USA 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Completed NLD | GBR | DEU 0
NCT03268954 Phase III Azacitidine + MLN4924 Azacitidine Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 11
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Active, not recruiting USA 0
NCT03306264 Phase III Decitabine Decitabine and Cedazuridine Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 2
NCT03326921 Phase I Fludarabine HA-1 TCR T cells HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Suspended USA 0
NCT03358719 Phase I Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT03383575 Phase II Azacitidine + Enasidenib Enasidenib Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Recruiting USA 0
NCT03386513 Phase Ib/II IMGN632 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 0
NCT03404193 Phase II Decitabine + Venetoclax Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03404726 Phase I BAY2402234 A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies Terminated USA | FRA 0
NCT03515512 Phase I Enasidenib IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Completed USA 0
NCT03531736 Phase I Rituximab Cyclophosphamide + Fludarabine T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia Active, not recruiting USA 0
NCT03564821 Phase I Ivosidenib IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Completed USA 0
NCT03613532 Phase I Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Recruiting USA 0
NCT03614728 Phase I Azacitidine + GSK3326595 GSK3326595 Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Terminated USA | CAN 0
NCT03670966 Phase Ib/II BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome Suspended USA 0
NCT03722407 Phase II Ruxolitinib Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion Active, not recruiting USA 0
NCT03746041 Phase I Abaloparatide + Bevacizumab A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes Completed USA 0
NCT03770429 Phase I Ceralasertib AZD6738 for Patients With Progressive MDS or CMML Recruiting USA 0
NCT03807063 Phase I Rimiducid Rivogenlecleucel Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT03814005 Phase I Azacitidine + MLN4924 A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment Completed USA | ESP 0
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03896269 Phase I CPX-351 CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Recruiting USA 0
NCT03922100 Phase Ib/II NMS-P088 Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML Recruiting ITA | FRA | ESP 0
NCT04016116 Phase II Pembrolizumab + Ruxolitinib Pembrolizumab Dual PD-1 and JAK2 Inhibition in Hematological Malignancies Withdrawn USA 0
NCT04041050 Phase I Navitoclax Navitoclax + Ruxolitinib A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL 7
NCT04139434 Phase I LP-108 Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Active, not recruiting USA | ESP 0
NCT04140487 Phase Ib/II Azacitidine + Gilteritinib + Venetoclax Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Active, not recruiting USA 0
NCT04146038 Phase II Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed USA 0
NCT04160052 Phase Ib/II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome Recruiting USA 0
NCT04167917 Phase I NTX-301 NTX-301 in MDS/AML Recruiting USA 0
NCT04239157 Phase II Azacitidine + Canakinumab Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04256317 Phase III ASTX030 ASTX030 + Azacitidine ASTX030 + Azacitidine + Cedazuridine A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML Recruiting USA 0
NCT04264806 Phase II ARGX-110 + Azacitidine Azacitidine A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) Withdrawn ITA | GBR | FRA | ESP | DEU | AUS 5
NCT04266301 Phase III Azacitidine Azacitidine + Sabatolimab Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 25
NCT04372433 Phase I Azacitidine + IO-202 IO-202 Azacitidine + IO-202 + Venetoclax IO-202 as Monotherapy and IO-202 Plus Azacitidine +/- Venetoclax in Patients in AML and CMML Recruiting USA 0
NCT04409639 Phase II Cobimetinib Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO) Recruiting USA 0
NCT04487106 Phase II Azacitidine + Trametinib + Venetoclax Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Completed USA 0
NCT04493138 Phase Ib/II Azacitidine + Quizartinib Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Recruiting USA 0
NCT04522895 Phase II Enasidenib IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT Active, not recruiting DEU 0
NCT04550442 Phase Ib/II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04581512 Phase Ib/II EP0042 Study to Evaluate the Safety and Tolerability of EP0042 Recruiting NLD | GBR | AUS 0
NCT04609826 Phase I JNJ74856665 Azacitidine + JNJ74856665 JNJ74856665 + Venetoclax A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Active, not recruiting GBR | FRA | ESP 1
NCT04655755 Phase Ib/II Decitabine and Cedazuridine + Venetoclax Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04708054 Phase II Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS Active, not recruiting USA 0
NCT04730258 Phase Ib/II CFI-400945 CFI-400945 + Decitabine Azacitidine + CFI-400945 A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML (TWT-202) Recruiting USA | CAN 1
NCT04734990 Phase Ib/II Azacitidine + Seclidemstat Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04937166 Phase I Azacitidine + DSP107 + Venetoclax A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies Recruiting USA 0
NCT04964518 Phase I APG-2575 + Azacitidine A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) Recruiting USA | AUS 0
NCT05024994 Phase II E7820 A Study of E7820 in People With Bone Marrow (Myeloid) Cancers Active, not recruiting USA 0
NCT05030675 Phase I Fostamatinib Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents Recruiting USA 0
NCT05107856 Phase I PRT1419 A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies Terminated USA 0
NCT05178342 Phase II CA-4948 Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS) Terminated DEU 0
NCT05209152 Phase I AMG 176 + Azacitidine AMG 176 AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia Completed USA 0
NCT05282459 Phase Ib/II Enasidenib Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation Recruiting USA 0
NCT05365035 Phase II Azacitidine + Venetoclax Cladribine + Cytarabine + Venetoclax A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts Recruiting USA 0
NCT05428969 Phase Ib/II Azacitidine + FP-1305 Azacitidine + FP-1305 + Venetoclax A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) Recruiting USA 1
NCT05455294 Phase I Decitabine + Navitoclax + Venetoclax Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Recruiting USA 0
NCT05549661 Phase I Onvansertib Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT05600894 Phase II Decitabine and Cedazuridine Decitabine and Cedazuridine + Venetoclax Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Excess Blasts Recruiting USA | CAN 0
NCT05636514 Phase I Decitabine and Cedazuridine + Defactinib Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS) Recruiting AUS 0
NCT05732103 Phase Ib/II CTX-712 A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes Recruiting USA 0
NCT05768711 Phase II Azacitidine + Venetoclax Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (AVENHIR) Recruiting FRA 0
NCT05787496 Phase I NC525 A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms Recruiting USA 0
NCT05823571 Phase I Itacitinib Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Recruiting USA 0
NCT05933070 Phase I INKmune A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL) Terminated GBR 1
NCT06071624 Phase I CD4CAR Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. Recruiting USA 0
NCT06085638 Phase Ib/II Azacitidine + Tamibarotene + Venetoclax Azacitidine + Tamibarotene Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia Withdrawn 0
NCT06159491 Phase Ib/II Azacitidine + Pacritinib Pacritinib in CMML Not yet recruiting USA 0
NCT06218628 Phase I Pacritinib + Talazoparib Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Recruiting USA 0
NCT06284460 Phase Ib/II ASTX029 ASTX029 + Decitabine and Cedazuridine Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms Not yet recruiting USA 0